tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Predictive Oncology Closes $343.5M Private Placements

Story Highlights
  • Predictive Oncology closed $343.5 million in private placements for a digital asset strategy.
  • The investment supports AI-driven drug discovery and enhances Aethir’s global infrastructure.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Predictive Oncology Closes $343.5M Private Placements

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Predictive Oncology ( (POAI) ) has provided an update.

On October 8, 2025, Predictive Oncology announced the closing of two private placements totaling approximately $343.5 million, which occurred on October 7, 2025. The funds will support the company’s new digital asset treasury strategy focused on ATH, a utility token of the Aethir ecosystem. This initiative aligns with Predictive Oncology’s AI-driven drug discovery efforts and aims to enhance Aethir’s infrastructure for AI and machine learning globally. The strategic move is expected to create significant value for the company and its shareholders.

The most recent analyst rating on (POAI) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Spark’s Take on POAI Stock

According to Spark, TipRanks’ AI Analyst, POAI is a Neutral.

The overall stock score is primarily impacted by the company’s poor financial performance, characterized by declining revenues and negative profit margins. Technical analysis provides some support with mixed signals, but the valuation remains unattractive due to negative earnings and no dividend yield. The absence of earnings call data and corporate events limits additional insights.

To see Spark’s full report on POAI stock, click here.

More about Predictive Oncology

Predictive Oncology is a leader in utilizing artificial intelligence and machine learning to accelerate drug discovery and development, particularly for cancer treatment. The company offers a scientifically validated AI platform, PEDAL, which predicts tumor response to drug compounds with high accuracy, supported by a vast biobank of human tumor samples and a CLIA laboratory facility. Headquartered in Pittsburgh, PA, Predictive Oncology collaborates with academic and industry partners to provide comprehensive AI-based drug discovery solutions.

Average Trading Volume: 80,309

Technical Sentiment Signal: Sell

Current Market Cap: $10.9M

See more data about POAI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1